T1	Participants 49 115	predominantly classic neovascular age-related macular degeneration
T2	Participants 425 590	2-year, Phase III, randomized, multicenter, double-masked trial, 423 patients received ranibizumab (0.3 or 0.5 mg) monthly + sham PDT or PDT + monthly sham injection
